Top

Published in:

Open Access 01-06-2011 | Research Paper

Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines

Authors: Yeon-Jin Kwon, Douglas R. Hurst, Adam D. Steg, Kun Yuan, Kedar S. Vaidya, Danny R. Welch, Andra R. Frost

Published in: Clinical & Experimental Metastasis | Issue 5/2011

Abstract

Gli1 is an established oncogene and its expression in Estrogen Receptor (ER) α negative and triple negative breast cancers is predictive of a poor prognosis; however, the biological functions regulated by Gli1 in breast cancer have not been extensively evaluated. Herein, Gli1 was over-expressed or down-regulated (by RNA interference and by expression of the repressor form of Gli3) in the ERα negative, human breast cancer cell lines MDA-MB-231 and SUM1315. Reduced expression of Gli1 in these two cell lines resulted in a decrease in migration and invasion. Gli1 over-expression increased the migration and invasion of MDA-MB-231 cells with a corresponding increase in expression of MMP-11. Silencing MMP-11 in MDA-MB-231 cells that over-expressed Gli1 abrogated the Gli1-induced enhancement of migration and invasion. Sustained suppression of Gli1 expression decreased growth of MDA-MB-231 in vitro by increasing apoptosis and decreasing proliferation. In addition, silencing of Gli1 reduced the numbers and sizes of pulmonary metastases of MDA-MB-231 in an in vivo experimental metastasis assay. In summary, Gli1 promotes the growth, survival, migration, invasion and metastasis of ERα negative breast cancer. Additionally, MMP-11 is up-regulated by Gli1 and mediates the migration and invasion induced by Gli1 in MDA-MB-231.

Available only for authorised users

Fernandez-Zapico ME (2008) Primers on molecular pathways GLI: more than just Hedgehog? Pancreatology 8(3):227–229PubMedCrossRef

Stecca B, Ruiz IAA (2010) Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol 2(2):84–95PubMedCrossRef

Dennler S, Andre J, Alexaki I et al (2007) Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 67(14):6981–6986PubMedCrossRef

Ji Z, Mei FC, Xie J et al (2007) Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 282(19):14048–14055PubMedCrossRef

Stecca B, Mas C, Clement V et al (2007) Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 104(14):5895–5900PubMedCrossRef

Noubissi FK, Goswami S, Sanek NA et al (2009) Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res 69(22):8572–8578PubMedCrossRef

Kinzler KW, Ruppert JM, Bigner SH et al (1988) The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature 332(6162):371–374PubMedCrossRef

Hahn H, Wojnowski L, Zimmer AM et al (1998) Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 4(5):619–622PubMedCrossRef

Nagai S, Nakamura M, Yanai K et al (2008) Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci 99(7):1377–1384PubMedCrossRef

10.

Karhadkar SS, Steven Bova G, Abdallah N et al (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431(7009):707–712PubMedCrossRef

11.

Nolan-Stevaux O, Lau J, Truitt ML et al (2009) GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 23(1):24–36PubMedCrossRef

12.

Fiaschi M, Rozell B, Bergstrom A et al (2009) Development of mammary tumors by conditional expression of GLI1. Cancer Res 69(11):4810–4817PubMedCrossRef

13.

Mukherjee S, Frolova N, Sadlonova A et al (2006) Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther 5(6):674–683PubMedCrossRef

14.

Kubo M, Nakamura M, Tasaki A et al (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64(17):6071–6074PubMedCrossRef

15.

ten Haaf A, Bektas N, von Serenyi S et al (2009) Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer 9:298PubMedCrossRef

16.

Xu L, Kwon YJ, Frolova N et al (2010) Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer. Breast Cancer Res Treat 123(1):59–71PubMedCrossRef

17.

Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41(1):40–47PubMedCrossRef

18.

Sadlonova A, Novak Z, Johnson MR et al (2005) Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res 7(1):R46–R59PubMedCrossRef

19.

Louro ID, Bailey EC, Li X et al (2002) Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res 62(20):5867–5873PubMed

20.

Foster KW, Ren S, Louro ID et al (1999) Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ 10(6):423–434PubMed

21.

Sadlonova A, Mukherjee S, Bowe DB et al (2007) Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease. Am J Pathol 170(3):1064–1076PubMedCrossRef

22.

Welch DR, Neri A, Nicolson GL (1983) Comparison of ‘spontaneous’ and ‘experimental’ metastasis using rat 13762 mammary adenocarcinoma metastatic cell clones. Invasion Metastasis 3(2):65–80PubMed

23.

Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527PubMedCrossRef

24.

Kim IS, Baek SH (2010) Mouse models for breast cancer metastasis. Biochem Biophys Res Commun 394(3):443–447PubMedCrossRef

25.

Li Y, Zhang H, Choi SC et al (2004) Sonic hedgehog signaling regulates Gli3 processing, mesenchymal proliferation, and differentiation during mouse lung organogenesis. Dev Biol 270(1):214–231PubMedCrossRef

26.

Kuperwasser C, Dessain S, Bierbaum BE et al (2005) A mouse model of human breast cancer metastasis to human bone. Cancer Res 65(14):6130–6138PubMedCrossRef

27.

Nakopoulou L, Panayotopoulou EG, Giannopoulou I et al (2002) Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients’ outcome. Mod Pathol 15(11):1154–1161PubMedCrossRef

28.

Engel G, Heselmeyer K, Auer G et al (1994) Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 58(6):830–835PubMedCrossRef

29.

Jia L, Wang S, Cao J et al (2007) siRNA targeted against matrix metalloproteinase 11 inhibits the metastatic capability of murine hepatocarcinoma cell Hca-F to lymph nodes. Int J Biochem Cell Biol 39(11):2049–2062PubMedCrossRef

30.

Pei D, Weiss SJ (1995) Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375(6528):244–247PubMedCrossRef

31.

Delany AM, Canalis E (2001) The metastasis-associated metalloproteinase stromelysin-3 is induced by transforming growth factor-beta in osteoblasts and fibroblasts. Endocrinology 142(4):1561–1566PubMedCrossRef

32.

Hyman JM, Firestone AJ, Heine VM et al (2009) Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci USA 106(33):14132–14137PubMedCrossRef

33.

Kameda C, Tanaka H, Yamasaki A et al (2009) The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res 29(3):871–879PubMed

34.

Das S, Harris LG, Metge BJ et al (2009) The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem 284(34):22888–22897PubMedCrossRef

35.

Rae JM, Creighton CJ, Meck JM et al (2007) MDA-MB-435 cells are derived from M14 melanoma cells—a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104(1):13–19PubMedCrossRef

36.

Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69(13):5292–5293PubMedCrossRef

37.

Kang Y, Siegel PM, Shu W et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549PubMedCrossRef

38.

Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518–524PubMedCrossRef

39.

Yoon JW, Kita Y, Frank DJ et al (2002) Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 277(7):5548–5555PubMedCrossRef

40.

Shevde LA, Samant RS, Paik JC et al (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23(2):123–133PubMedCrossRef

41.

Martin MD, Carter KJ, Jean-Philippe SR et al (2008) Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68(15):6251–6259PubMedCrossRef

42.

Olmeda D, Moreno-Bueno G, Flores JM et al (2007) SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res 67(24):11721–11731PubMedCrossRef

43.

Jechlinger M, Sommer A, Moriggl R et al (2006) Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Investig 116(6):1561–1570PubMedCrossRef

44.

Motrescu ER, Rio MC (2008) Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem 389(8):1037–1041PubMedCrossRef

45.

Manes S, Mira E, Barbacid MM et al (1997) Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 272(41):25706–25712PubMedCrossRef

46.

Motrescu ER, Blaise S, Etique N et al (2008) Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene 27(49):6347–6355PubMedCrossRef

47.

Fiorentino M, Fu L, Shi YB (2009) Mutational analysis of the cleavage of the cancer-associated laminin receptor by stromelysin-3 reveals the contribution of flanking sequences to site recognition and cleavage efficiency. Int J Mol Med 23(3):389–397PubMed

48.

Basset P, Bellocq JP, Wolf C et al (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348(6303):699–704PubMedCrossRef

49.

Wolf C, Rouyer N, Lutz Y et al (1993) Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90(5):1843–1847PubMedCrossRef

50.

Ahmad A, Hanby A, Dublin E et al (1998) Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol 152(3):721–728PubMed

51.

Fromigue O, Louis K, Wu E et al (2003) Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase. Int J Cancer 106(3):355–363PubMedCrossRef

52.

Dillon RL, Muller WJ (2010) Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 70(11):4260–4264PubMedCrossRef

53.

Viala E, Pouyssegur J (2004) Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann N Y Acad Sci 1030:208–218PubMedCrossRef

54.

Clemmons DR (2007) Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6(10):821–833PubMedCrossRef

55.

Furstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3(5):298–302PubMedCrossRef

56.

Kasper G, Reule M, Tschirschmann M et al (2007) Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway. BMC Cancer 7:12PubMedCrossRef

Title: Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines
Authors: Yeon-Jin Kwon
Douglas R. Hurst
Adam D. Steg
Kun Yuan
Kedar S. Vaidya
Danny R. Welch
Andra R. Frost
Publication date: 01-06-2011
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9382-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity

Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors

Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells

Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma

Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells

Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature

Keynote webinar | Spotlight on antibody–drug conjugates in cancer